1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus

Journal of Virology

Volumn 84, Issue 6, 2010, Pages 2923-2934

  Nyanguile, Origène ^a   Devogelaere, Benoit ^a   Vijgen, Leen ^a   Van Den Broeck, Walter ^a   Pauwels, Frederik ^a   Cummings, Maxwell D ^a   De Bondt, Hendrik L ^b   Vos, Ann M ^a   Berke, Jan M ^a   Lenz, Oliver ^a   Vandercruyssen, Geneviève ^a   Vermeiren, Katrien ^a   Mostmans, Wendy ^a   Dehertogh, Pascale ^a   Delouvroy, Frédéric ^a   Vendeville, Sandrine ^a   VanDyck, Koen ^a   Dockx, Koen ^a   Cleiren, Erna ^a   Raboisson, Pierre ^a   Simmen, Kenneth A ^a   Fanning, Gregory C ^a   more..

^a HCV Research   (Belgium)

^b Institute for the Promotion of Innovation By Science and Technology in Flanders   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; ENZYME INHIBITOR; RNA DIRECTED RNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING SITE; DRUG INHIBITION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYDROPHOBICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS RESISTANCE; X RAY CRYSTALLOGRAPHY;

ANTIVIRAL AGENTS; BENZODIAZEPINES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HEPACIVIRUS; HEPATITIS C; HUMANS; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; REPLICON; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 77649106809     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01980-09     Document Type: Article

References (49)

1. Alter, M. J., D. Kruszon-Moran, O. V. Nainan, G. M. McQuillan, F. Gao, L. A. Moyer, R. A. Kaslow, and H. S. Margolis. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:556-562.
2. Anadys Pharmaceuticals, Inc. 9 January 2009. ANA598 demonstrates potent antiviral activity in an early clinical study in HCV-infected patients. http: //www.medicalnewstoday.com/articles/134837.php.
3. Behrens, S. E., L. Tomei, and R. De Francesco. 1996. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22.
4. Biswal, B. K., M. M. Cherney, M. Wang, L. Chan, C. G. Yannopoulos, D. Bilimoria, O. Nicolas, J. Bedard, and M. N. James. 2005. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by nonnucleoside inhibitors. J. Biol. Chem. 280:18202-18210.
5. Biswal, B. K., M. Wang, M. M. Cherney, L. Chan, C. G. Yannopoulos, D. Bilimoria, J. Bedard, and M. N. James. 2006. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J. Mol. Biol. 361:33-45.
6. Bressanelli, S., L. Tomei, A. Roussel, I. Incitti, R. L. Vitale, M. Mathieu, R. De Francesco, and F. A. Rey. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 96: 13034-13039.
7. Chen, C. M., Y. He, L. Lu, H. B. Lim, R. L. Tripathi, T. Middleton, L. E. Hernandez, D. W. Beno, M. A. Long, W. M. Kati, T. D. Bosse, D. P. Larson, R. Wagner, R. E. Lanford, W. E. Kohlbrenner, D. J. Kempf, T. J. Pilot-Matias, and A. Molla. 2007. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob. Agents Chemother. 51: 4290-4296.
8. Copeland, R. A., D. L. Pompliano, and T. D. Meek. 2006. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5:730-739.
9. Dhanak, D., K. J. Duffy, V. K. Johnston, J. Lin-Goerke, M. Darcy, A. N. Shaw, B. Gu, C. Silverman, A. T. Gates, M. R. Nonnemacher, D. L. Earnshaw, D. J. Casper, A. Kaura, A. Baker, C. Greenwood, L. L. Gutshall, D. Maley, A. DelVecchio, R. Macarron, G. A. Hofmann, Z. Alnoah, H. Y. Cheng, G. Chan, S. Khandekar, R. M. Keenan, and R. T. Sarisky. 2002. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277:38322-38327.
10. Di Marco, S., C. Volpari, L. Tomei, S. Altamura, S. Harper, F. Narjes, U. Koch, M. Rowley, R. De Francesco, G. Migliaccio, and A. Carfi. 2005. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J. Biol. Chem. 280:29765-29770.
11. Esteban, J. I., S. Sauleda, and J. Quer. 2008. The changing epidemiology of hepatitis C virus infection in Europe. J. Hepatol. 48:148-162.
12. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
13. Gray, F., L. Amphlett, H. Bright, L. Chambers, A. Cheasty, R. Fenwick, D. Haigh, D. Hartley, P. Howes, R. Jarvest, F. Mirzai, F. Nerozzi, N. Parry, M. Slater, S. Smith, P. Thommes, C. Wilkinson, and E. Williams. 2007. GSK625433: a novel and highly potent inhibitor of the HCV NS5B polymerase. In 42nd Meet. Eur. Assoc. Study Liver Dis. http://www.natap.org/2007/ EASL/EASL-13.htm.
14. Gu, B., V. K. Johnston, L. L. Gutshall, T. T. Nguyen, R. R. Gontarek, M. G. Darcy, R. Tedesco, D. Dhanak, K. J. Duffy, C. C. Kao, and R. T. Sarisky. 2003. Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J. Biol. Chem. 278:16602-16607.
15. Hang, J. Q., Y. Yang, S. F. Harris, V. Leveque, H. J. Whittington, S. Rajyaguru, G. Ao-Ieong, M. F. McCown, A. Wong, A. M. Giannetti, S. Le Pogam, F. Talamas, N. Cammack, I. Najera, and K. Klumpp. 2009. Slow-binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J. Biol. Chem. 284:15517-15529.
16. Herlihy, K. J., J. P. Graham, R. Kumpf, A. K. Patick, R. Duggal, and S. T. Shi. 2008. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob. Agents Chemother. 52:3523-3531.
17. Hnatyszyn, H. J. 2005. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir. Ther. 10:1-11.
18. Hoofnagle, J. H. 2002. Course and outcome of hepatitis C. Hepatology 36:S21-S29.
19. Howe, A. Y., H. Cheng, S. Johann, S. Mullen, S. K. Chunduru, D. C. Young, J. Bard, R. Chopra, G. Krishnamurthy, T. Mansour, and J. O'Connell. 2008. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 52:3327-3338.
20. Ikegashira, K., T. Oka, S. Hirashima, S. Noji, H. Yamanaka, Y. Hara, T. Adachi, J. Tsuruha, S. Doi, Y. Hase, T. Noguchi, I. Ando, N. Ogura, S. Ikeda, and H. Hashimoto. 2006. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. J. Med. Chem. 49:6950-6953.
21. Jacobson, I., P. Pockros, J. Lalezari, E. Lawitz, M. Rodrigues-Torres, E. DeJesus, F. Haas, C. Martorell, R. Pruitt, K. Durham, S. Srinivasan, M. Rosario, S. Jagannatha, and J. Hammond. 2009. Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. In 44th Annu. Meet. Eur. Assoc. Study Liver. http://www.natap.org/2009/ EASL/EASL-34.htm.
22. Karlsson, R., P. S. Katsamba, H. Nordin, E. Pol, and D. G. Myszka. 2006. Analyzing a kinetic titration series using affinity biosensors. Anal. Biochem. 349:136-147.
23. Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624.
24. Lawitz, E., C. Cooper, M. Rodriguez-Torres, R. Ghalib, R. Lalonde, A. Sheikh, B. Bourgault, N. Chauret, L. Proulx, and J. McHutchison. 2009. Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor in patients with chronic HCV genotype-1 infection. J. Hepatol. 50(Suppl.):S37.
25. Le Pogam, S., A. Seshaadri, A. Kosaka, S. Chiu, H. Kang, S. Hu, S. Rajyaguru, J. Symons, N. Cammack, and I. Najera. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:1205-1216.
26. Lesburg, C. A., M. B. Cable, E. Ferrari, Z. Hong, A. F. Mannarino, and P. C. Weber. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:937-943.
27. Lohmann, V., S. Hoffmann, U. Herian, F. Penin, and R. Bartenschlager. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019.
28. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
29. Love, R. A., H. E. Parge, X. Yu, M. J. Hickey, W. Diehl, J. Gao, H. Wriggers, A. Ekker, L. Wang, J. A. Thomson, P. S. Dragovich, and S. A. Fuhrman. 2003. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77:7575-7581.
30. Lutchman, G., S. Danehower, B. C. Song, T. J. Liang, J. H. Hoofnagle, M. Thomson, and M. G. Ghany. 2007. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132:1757-1766.
31. Manns, M. P., H. Wedemeyer, and M. Cornberg. 2006. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350-1359.
32. McGowan, D., O. Nyanguile, M. D. Cummings, S. Vendeville, K. Vandyck, W. Van den Broeck, C. W. Boutton, H. De Bondt, L. Quirynen, K. Amssoms, J. F. Bonfanti, S. Last, K. Rombauts, A. Tahri, L. Hu, F. Delouvroy, K. Vermeiren, G. Vandercruyssen, L. Van der Helm, E. Cleiren, W. Mostmans, P. Lory, G. Pille, K. Van Emelen, G. Fanning, F. Pauwels, T. I. Lin, K. Simmen, and P. Raboisson. 2009. 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett. 19:2492-2496.
33. Menon, R., D. Cohen, A. Nada, E. O. Dumas, Y.-L. Chiu, T. Podsadecki, W. Awni, B. Bernstein, and C. E. Klein. 2009. Pharmacokinetics, safety and tolerability of the HCV polymerase inhibitor ABT-333 following single ascending doses in healthy adult volunteers. In 44th Annu. Meet. Eur. Assoc. Study Liver. http://www.natap.org/2009/EASL/EASL-53.htm.
34. Middleton, T., Y. He, T. Pilot-Matias, R. Tripathi, B. H. Lim, A. Roth, C. M. Chen, G. Koev, T. I. Ng, P. Krishnan, R. Pithawalla, R. Mondal, T. Dekhtyar, L. Lu, H. Mo, W. M. Kati, and A. Molla. 2007. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J. Virol. Methods. 145:137-145.
35. Nguyen, M. H., and E. B. Keeffe. 2005. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin. Gastroenterol. Hepatol. 3:S97-S101.
36. Nyanguile, O., F. Pauwels, W. Van den Broeck, C. W. Boutton, L. Quirynen, T. Ivens, L. van der Helm, G. Vandercruyssen, W. Mostmans, F. Delouvroy, P. Dehertogh, M. D. Cummings, J. F. Bonfanti, K. A. Simmen, and P. Raboisson. 2008. 1,5-Benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors. Antimicrob. Agents Chemother. 52: 4420-4431.
37. O'Farrell, D., R. Trowbridge, D. Rowlands, and J. Jager. 2003. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J. Mol. Biol. 326:1025-1035.
38. Pauwels, F., W. Mostmans, L. M. Quirynen, L. van der Helm, C. W. Boutton, A. S. Rueff, E. Cleiren, P. Raboisson, D. Surleraux, O. Nyanguile, and K. A. Simmen. 2007. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J. Virol. 81:6909-6919.
39. Payan, C., F. Roudot-Thoraval, P. Marcellin, N. Bled, G. Duverlie, I. Fouchard-Hubert, P. Trimoulet, P. Couzigou, D. Cointe, C. Chaput, C. Henquell, A. Abergel, J. M. Pawlotsky, C. Hezode, M. Coude, A. Blanchi, S. Alain, V. Loustaud-Ratti, P. Chevallier, C. Trepo, V. Gerolami, I. Portal, P. Halfon, M. Bourliere, M. Bogard, E. Plouvier, C. Laffont, G. Agius, C. Silvain, V. Brodard, G. Thiefin, C. Buffet-Janvresse, G. Riachi, F. Grattard, T. Bourlet, F. Stoll-Keller, M. Doffoel, J. Izopet, K. Barange, M. Martinot-Peignoux, M. Branger, A. Rosenberg, P. Sogni, M. L. Chaix, S. Pol, V. Thibault, P. Opolon, A. Charrois, L. Serfaty, B. Fouqueray, J. D. Grange, J. J. Lefrere, and F. Lunel-Fabiani. 2005. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP GenoCII Study. J. Viral Hepat. 12:405-413.
40. Pietschmann, T., A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F. L. Cosset, and R. Bartenschlager. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413.
41. Pockros, P., M. Rodrigues-Torres, S. Villano, E. Maller, and M. Chojkier. 2009. A phase 2, randomized study of HCV-796 in combination with pegylated-interferon (PEG) plus ribavirin versus PEG plus RBV in hepatitis C virus genotype-1 infection. J. Hepatol. 50:S7.
42. Rydberg, E. H., A. Cellucci, L. Bartholomew, M. Mattu, G. Barbato, S. W. Ludmerer, D. J. Graham, S. Altamura, G. Paonessa, R. De Francesco, G. Migliaccio, and A. Carfi. 2009. Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors. J. Mol. Biol. 390:1048-1059.
43. Shi, S. T., K. J. Herlihy, J. P. Graham, J. Nonomiya, S. V. Rahavendran, H. Skor, R. Irvine, S. Binford, J. Tatlock, H. Li, J. Gonzalez, A. Linton, A. K. Patick, and C. Lewis. 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 53:2544-2552.
44. Simmonds, P., J. Bukh, C. Combet, G. Deleage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspe, C. Kuiken, G. Maertens, M. Mizokami, D. G. Murphy, H. Okamoto, J. M. Pawlotsky, F. Penin, E. Sablon, I. T. Shin, L. J. Stuyver, H. J. Thiel, S. Viazov, A. J. Weiner, and A. Widell. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
45. Sulkowski, M. S. 2007. Specific targeted antiviral therapy for hepatitis C. Curr. Gastroenterol. Rep. 9:5-13.
46. Sy, T., and M. M. Jamal. 2006. Epidemiology of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 3:41-46.
47. Vandyck, K., M. D. Cummings, O. Nyanguile, C. W. Boutton, S. Vendeville, D. McGowan, B. Devogelaere, K. Amssoms, S. Last, K. Rombauts, A. Tahri, P. Lory, L. Hu, D. A. Beauchamp, K. Simmen, and P. Raboisson. 2009. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase. J. Med. Chem. 52:4099-4102.
48. Wang, M., K. K. Ng, M. M. Cherney, L. Chan, C. G. Yannopoulos, J. Bedard, N. Morin, N. Nguyen-Ba, M. H. Alaoui-Ismaili, R. C. Bethell, and M. N. James. 2003. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 278:9489-9495.
49. Zhong, W., E. Ferrari, C. A. Lesburg, D. Maag, S. K. Ghosh, C. E. Cameron, J. Y. Lau, and Z. Hong. 2000. Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase. J. Virol. 74:9134-9143